Masimo Co. (NASDAQ:MASI) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC cut its holdings in shares of Masimo Co. (NASDAQ:MASI) by 8.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,444 shares of the medical equipment provider’s stock after selling 834 shares during the period. Intech Investment Management LLC’s holdings in Masimo were worth $1,259,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. NBC Securities Inc. lifted its position in shares of Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the last quarter. Fifth Third Bancorp boosted its position in shares of Masimo by 16.4% in the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock valued at $88,000 after purchasing an additional 98 shares during the period. Oak Thistle LLC increased its stake in Masimo by 5.2% in the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after purchasing an additional 103 shares in the last quarter. GAMMA Investing LLC raised its holdings in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares during the period. Finally, HHM Wealth Advisors LLC lifted its stake in Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Stock Down 3.1 %

Shares of MASI stock opened at $172.26 on Wednesday. Masimo Co. has a twelve month low of $91.60 and a twelve month high of $178.27. The company has a market capitalization of $9.22 billion, a price-to-earnings ratio of 118.80 and a beta of 0.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock’s 50 day simple moving average is $144.76 and its 200 day simple moving average is $128.38.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same period in the previous year, the business posted $0.63 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. As a group, research analysts predict that Masimo Co. will post 4.04 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. BTIG Research boosted their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Wells Fargo & Company raised their target price on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a research note on Wednesday, November 6th. Finally, Piper Sandler lifted their target price on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and a consensus target price of $167.00.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.